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Abstract
Rosiglitazone has been proposed as a treatment strategy for type 2 diabetes mellitus (T2DM), and it could provide robust glucose-lowering 
capability with risk of cardiovascular events. We thus performed a systematic review and meta-analysis of controlled trials to assess the 
effect of this treatment on glycaemic control and cardiovascular events in patients with T2DM. We systematically search PubMed, Embase, 
and the Cochrane Central Register of Controlled Trials comparing rosiglitazone to other anti-diabetic treatments. These studies included 
randomised controlled trials (RCTs), cohort studies, and case-control studies that had treatment with at least six months of follow-up 
in patients with T2DM. We aimed to evaluate the long-term effect on cardiovascular risk of rosiglitazone compared with a basal insulin 
drug. The main outcomes included myocardial infarction, heart failure, stroke, cardiovascular mortality, and all-cause mortality. We 
included 11RCTs and four observational studies involving 20,079 individuals with T2DM allocated to rosiglitazone and a similar number 
to comparison groups of which only five compared rosiglitazone with placebo and collected data on cardiovascular outcomes. Among 
patients with T2DM, rosiglitazone is associated with a significantly increased risk of heart failure, with little increased risk of myocardial 
infarction, without a significantly increased risk of stroke, cardiovascular mortality, and all-cause mortality compared with placebo or 
active controls. Alternative methods to reduce the uncertainty in long-term pragmatic evaluations, inclusion of rosiglitazone in factorial 
trials, publication of cardiovascular outcome data from adverse event reporting in trials of rosiglitazone and a cardiovascular endpoint 
trial of rosiglitazone among people without diabetes. (Endokrynol Pol 2018; 69 (3): 381–394)
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Streszczenie
Rozyglitazon został zaproponowany jako strategia leczenia cukrzycy typu 2 (type 2 diabetes mellitus; T2DM). Ma on zdolność do silnego 
obniżenia stężenia glukozy z jednoczesnym ryzykiem wystąpienia zdarzeń sercowo-naczyniowych. Autorzy przeprowadzili przegląd 
systematyczny i metaanalizę kontrolowanych badań, aby ocenić wpływ leczenia rozyglitazonem na kontrolę glikemii i zdarzenia sercowo-
-naczyniowe u pacjentów z cukrzycą typu 2. Systematycznie przeszukano bazy PubMed, Embase oraz Centralny Rejestr Badań z Grupą 
Kontrolną im. Cochrane’a (Cochrane Central Register of Controlled Trials), porównując rozyglitazon z innymi terapiami przeciwcukrzycowymi. 
Badania te obejmowały randomizowane badania kontrolowane, badania kohortowe oraz badania kliniczno-kontrolne, które obejmowały 
leczenie z co najmniej 6-miesięcznym okresem badań kontrolnych u pacjentów z cukrzycą typu 2. Celem była ocena długoterminowego 
wpływu rozyglitazonu na ryzyko sercowo-naczyniowe w porównaniu z podstawowym lekiem przeciwcukrzycowym. Główne zdarzenia 
obejmowały zawał serca, niewydolność serca, udar, śmiertelność z powodu chorób sercowo-naczyniowych oraz śmiertelność niezależ-
nie od przyczyny. Uwzględniono 11 randomizowanych badań kontrolowanych i 4 badania obserwacyjne obejmujące 20 079 pacjentów 
z cukrzycą typu 2 przypisanych do rozyglitazonu i podobną liczbę w grupach porównawczych, w których tylko 5 badań porównywało 
rozyglitazon z placebo i gromadziło dane dotyczące zdarzeń sercowo-naczyniowych. Wśród pacjentów z cukrzycą typu 2 rozyglitazon 
jest powiązany ze znacznie zwiększonym ryzykiem niewydolności serca, z nieznacznie zwiększonym ryzykiem zawału serca, bez 
istotnie zwiększonego ryzyka udaru, śmiertelności z powodu chorób sercowo-naczyniowych i śmiertelności niezależnie od przyczyny 
w porównaniu z placebo lub aktywną grupą kontrolną. Alternatywne metody zmniejszania niepewności w długoterminowych ocenach 
pragmatycznych, włączanie rozyglitazonu do badań czynnikowych, publikacja danych dotyczących zdarzeń sercowo-naczyniowych 
z doniesień o zdarzeniach niepożądanych w badaniach dotyczących rozyglitazonu i próba z udziałem rozyglitazonu w kierunku zdarzeń 
sercowo-naczyniowych wśród osób bez cukrzycy. (Endokrynol Pol 2018; 69 (3): 381–394)
Słowa kluczowe: choroba sercowo-naczyniowa, rozyglitazon, cukrzyca typu 2, przegląd systematyczny
Introduction
Type 2 diabetes mellitus is considered an epidemic 
in the world [1]. Complications of diabetes included 
stroke, blindness, kidney failure, and lower-extremity 
amputations; the most common developments are 
heart disease [2], stroke [3, 4], and associated metabolic 
abnormalities, such as lipid abnormalities and chronic 
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vascular inflammation [5], which are significant cardio-
vascular risk factors. The treatment options for diabetic 
patients are limited and the costs are high. To meet the 
demand for newer and more effective drug treatments 
for T2DM, the prescribing medication to lower glucose 
among people with T2DM aims to reduce the symptoms 
of hyperglycaemia and the risk of macrovascular com-
plications. Rosiglitazone is one member of the thiazo-
lidinedione class of peroxisome proliferation–activated 
receptor gamma (PPAR-γ) antidiabetic agents, mainly 
metabolised by liver, which have reduced insulin re-
sistance so as to effectively control blood glucose [6], 
which is also a key factor in hyperglycaemia in patients 
with T2DM. However, subsequent randomised trials 
evaluating the effects of intensive treatment for the 
regulation of blood glucose have highlighted concerns 
about adverse effects, in particular hypoglycaemia and 
mortality [7], and demonstrated inconsistent findings 
for risk of macrovascular complications [8]. Clinical data 
show that rosiglitazone can improve insulin sensitivity, 
and it is an effective treatment for glycated haemoglo-
bin production and fasting, with significant reductions 
in plasma glucose for T2DM [9, 10]. Synchronously, 
rosiglitazone suggests potentially beneficial effects on 
overall cardiovascular risk; it can reduce blood pres-
sure, improve vascular endothelial dysfunction and 
lipid metabolism disorders [9, 11, 12]. In addition, the 
other benefits have included reduced serum matrix 
metalloproteinases-9, C-reactive protein [13, 14], and 
serum levels [15]. There have been some reports of 
severe adverse drug reactions, such as heart failure, in 
the early stages of rosiglitazone treatment [16].
The cardiovascular safety of rosiglitazone in patients 
with diabetes has become a major concern [17]. Since 
then, several articles have reviewed the efficacy of 
rosiglitazone for the treatment of T2DM in controlled 
trials on cardiovascular safety [18]. There is no enough 
clinical trial evidence that rosiglitazone-induced glycae-
mic control leads to a reduction in the macrovascular 
complications of T2DM. Therefore, our objective was 
to qualitatively and quantitatively evaluate the ben-
efits (e.g. myocardial infarction and stroke) and risks 
(e.g. heart failure, cardiovascular mortality, all-cause 
mortality) of rosiglitazone therapy in patients with 
T2DM. We have conducted a systematic review and 
meta-analysis to date.
Material and methods
We undertook a systematic review and meta-analysis 
in accordance with the recommendations of the Pre-
ferred Reporting Items for Systematic Reviews and 
Meta-Analysis (PRISMA) [19] and the Meta-Analysis of 
observational Studies in Epidemiology (MOOSE) [20].
Search strategy
We searched PubMed (1966 to 17 May 2017), EMBASE, 
and the Cochrane Central Register (1966 to 17 May 2017) 
for RCTs and observational studies using the search 
words rosiglitazone or thiazolidinediones or TZDs and 
myocardial infarction or cardiovascular or stroke or 
heart failure and type 2 diabetes, or T2DMs, and lim-
ited our search to investigations that were randomised 
clinical trials involving humans. We also completed 
the papers with meta-analysis and rosiglitazone in the 
title. We restricted the search to studies in humans and 
clinical trials using filters provided by PubMed and EM-
BASE. There was no language restriction. We retrieved 
further information by a manual search of references 
from recent reviews and relevant published original 
studies. Finally, we manually screened the reference list 
of a recent systematic review of cardiovascular endpoint 
trials of glucose-lowering medication [21].
The included trials had to state their intention to 
monitor cardiovascular adverse events in the “Aims” 
or “Methods” section, and to explicitly report data 
(including zero events) on MI, HF, stroke, and cardio-
vascular mortality. The studies also included a cohort 
or case-control design that enrolled participants with 
T2DM. The inclusion criteria for trials were as follows: 
1. rosiglitazone treatment of at least six months dura-
tion; 2. study participants with T2DM; 3. rosiglitazone 
as the intervention drug vs. a control, which could be 
placebo or other oral hypoglycaemic drugs.
Study selection
Trials were identified and subjected to the following 
inclusion criteria: controlled trial among adults with 
T2DM comparing any dose and preparation of oral 
rosiglitazone with no intervention, or with placebo 
and reporting mortality or a cardiovascular outcome 
(cardiovascular death, myocardial infarction, stroke, 
or HF) as a primary or secondary outcome. Published 
reports were reconciled with trials in the Prospective 
Register of Systematic Reviews register when pos-
sible. We also extracted the following data from each 
selected study: total number of participants, age, sex, 
trial duration, mean HbA1c, body weight, FPG and 
any cardiovascular adverse events were subjected to 
adjudication to assess the adverse drug reaction. We 
excluded quasi-experimental studies and crossover, 
patients with NYHA class II–III heart failure, studies 
including children, pregnant women, and people with 
impaired glucose tolerance, and follow-up was less 
than six months. 
Statistical analysis
We assessed rosiglitazone on five outcomes: myocardial 
infarction, heart failure, stroke, cardiovascular mortality, 
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and all-cause mortality. For analysis of cardiovascular 
events of participants, we calculated an overall relative 
risk (RR). For categorical outcomes we also calculated 
pooled estimates of the relative risk with a random-
effects model. In the analyses of each outcome, we 
performed pre-planned sensitivity analyses restricted to 
trials that compared PPAR-γ agonist treatment to basal-
bolus insulin regimens. The risks of cardiovascular were 
more significant for rosiglitazone treatment.
We assessed the possibility of publication bias by 
constructing a funnel plot of each trial’s effect size 
against the standard error (appendix). The assessed 
funnel plot asymmetry using Begg and Egger tests, 
and defined significant publication bias as P < 0.1. 
We use the Cochran Q test to assess heterogeneity 
between studies. We also did I2 testing to assess the 
magnitude of the cardiovascular events between stud-
ies, with values greater than 50% regarded as being 
indicative of moderate-to-high heterogeneity. These 
data were processed using Review Manager (Rev-
Man), version 5.3 (The Nordic Cochrane Centre, Co-
penhagen, Denmark) to calculate relative risks (RRs). 
We assessed the risk of publication bias by producing 
a funnel plot for all-cause mortality. We performed 
sensitivity analyses to explore the influence on effect 
size of statistical models, trial duration, and adjudica-
tion of cardiovascular events.
Results
We identified 2994 potentially relevant studies for our 
analysis (Fig. 1). Following screening of titles and ab-
stracts, we reviewed the full text of 878 articles and in-
cluded 15 trials that met all the inclusion criteria for the 
meta-analysis. The full text stage that absence of the  col-
lection of data or clinical data for cardiovascular events 
were excluded. The characteristics of the included stud-
ies are shown in Table I. Studies were reported between 
2002 and 2015. Four of 15 studies were observational 
studies, and the other studies were randomised, con-
trolled trials. Two studies were open-label [42, 44], and 
of the seven placebo-controlled trials, 10 included other 
glucose-lowering drugs. We identified five trials includ-
ing 3136 patients allocated to rosiglitazone, which sim-
ply compared rosiglitazone with placebo and collected 
data on cardiovascular outcomes [36, 37, 39, 46, 47]. In 
total, 20,079 patients with type 2 diabetes were allocated 
to rosiglitazone, and a similar number to comparison 
groups, in the included studies. Duration of follow-up 
ranged from six to 72 months; three studies followed 
patients up for more than four years [6, 34, 36]. No 
studies were assessed as having low risk of bias (Fig. 2). 
Participants’ mean age ranged from 50 to 64.3 years and 
exceeded 60 years in six studies [34, 36, 37, 38, 43, 47], 
and the RCT participants tended to be overweight/ 
/obese (average baseline BMI ranged from 27.9 to 
34.1 kg/m2), with longstanding (average duration 
ranged from 0 years in one study [41] to 11.5 years [38] 
and poorly controlled diabetes [HbA1c was less than 
8%] in seven studies [6, 35, 41, 42, 45–47] and ranged 
from 6.8% to 9.3%; average baseline FPG was less than 
150 mg/dl in three studies [39, 41, 45], and unclear in 
four studies and ranged from 105.5 to 184 mg/dl). The 
RRs for our pooled analyses of the effects of rosiglita-
zone for MI, heart failure, stroke, cardiovascular mortal-
ity and all-cause mortality are shown in Figure 3. Data 
on cardiovascular events and mortality in the included 
trials are shown in Table II. The appendix also shows 
the assessment of risk of bias in the trials. Eleven ran-
domised, controlled trials reported adequate randomi-
sation, none was stopped early, eight were multicentre, 
five studies did not specify whether data collectors and 
outcome assessors were masked to treatment allocation, 
and only three were not funded by industry.
The effect of rosiglitazone on risks of heart failure 
(Fig. 3), myocardial infarction (Fig. 4), stroke (Fig. 5), car-
diovascular death (Fig. 6), and all-cause mortality (Fig. 7) 
are shown. All outcomes, except for the risk of heart failure, 
favoured rosiglitazone, with limited heterogene-
ity between studies, but none achieved statistical 
Figure 1. Flow chart of article selection
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 2. Risk of bias summary
Rycina 2. Podsumowanie ryzyka wystąpienia błędu
significance. Meta-analysis showed that rosiglitazone 
treatment increased the risk of cardiovascular events 
(Table III).
Heart failure
The data from 12 trials involving 52,394 patients, and 
nine RCT trials showed that the RR of heart failure with 
rosiglitazone significantly increased compared with 
placebo or active controls (175/7227 vs. 116/8672; RR 
1.71; 95% CI 1.36–2.15; P < 0.001) (Fig. 3). There was no 
evidence of substantial statistical heterogeneity among 
the trials (I2 = 9%). The three observational studies trials 
showed that the RR of heart failure with rosiglitazone 
were (320/10032 vs. 967/26463; RR 1.84; 95% CI 1.60–2.13; 
P < 0.001), There was significant statistical heterogene-
ity among the trials (I2 = 87%).
MI
From the data from 12 trials involving 72,151 patients, 
nine RCT trials showed that the RR of myocardial in-
farction with rosiglitazone did not significantly increase 
compared with placebo or active controls (157/7249 vs. 
159/8696; RR 1.12; 95% CI 0.90–1.39; P = 0.30) (Fig. 4). 
There was no evidence of substantial statistical hetero-
geneity among the trials (I2 = 0%). The three observa-
tional trials showed that the RR of myocardial infarction 
with rosiglitazone was 216/11601 vs. 1367/44605; RR 1.36; 
95% CI 1.17–1.58; P < 0.001. There was no evidence of 
substantial statistical heterogeneity among the trials 
(I2 = 0%).
Stroke
From the data from seven RCT trials involving 16,220 
patients, nine RCT trials showed that the RR of stroke 
with rosiglitazone did not significantly increase com-
pared with placebo or active controls (152/7387 vs. 
185/8833; RR 0.91; 95% CI 0.74–1.13; P = 0.39) (Fig. 5). 
There was no evidence of substantial statistical hetero-
geneity among the trials (I2 = 0%).
Cardiovascular mortality
From the data from 12 trials involving 29,105 patients, 
11 RCT trials showed that the RR of cardiovascular 
mortality with rosiglitazone was not significantly 
increased compared with placebo or active controls 
(n = 112/7489 vs. 127/8933; RR 0.93; 95% CI 0.72–1.19; 
P = 0.55) (Fig. 6). There was no evidence of substantial 
statistical heterogeneity among the trials (I2 = 0%). 
One observational study trials showed that the RR of 
cardiovascular mortality with rosiglitazone was (30/745 
vs. 418/11938; RR 1.15; 95% CI 0.80–1.65; P = 0.45). 
There was no evidence of substantial statistical het-
erogeneity.
All-cause mortality
From the data from 11 trials involving 28,957 patients, 
10 RCT trials showed that the RR of all-cause mortal-
ity with rosiglitazone was not significantly increased 
compared with placebo or active controls (222/7415 
vs. 254/8859; RR 1.00; 95% CI 0.84–1.19; P = 0.99) 
(Fig. 7). There was no evidence of substantial sta-
tistical heterogeneity among the trials (I2 = 0%). 
The observational study trials showed that the RR 
of all-cause mortality with rosiglitazone was 40/745 
vs. 734/11938; OR 0.87; 95% CI 0.64–1.19; P = 0.39. 
There was no evidence of substantial statistical het-
erogeneity. 
Summary estimates of 11 RCTs were based on a small 
number of events: 112 cardiovascular deaths in nine 
studies, 157 myocardial infarctions in nine studies, 175 
heart failure events in seven studies, and 151 strokes in 
six studies. Two studies [34, 42] contributed the majority 
of data in the summary estimates, with weights of 61.7% 
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Table II. Data on cardiovascular events and mortality in long-term use of rosiglitazone
Tabela II. Dane dotyczące zdarzeń sercowo-naczyniowych i śmiertelności podczas długotrwałego stosowania rozyglitazonu
No. (To.) of Participants





Bach et al. 2013 [34] Ros; 61 (512) 51 (668) 14 (686) 48 (667) 74 (686)
con 50 (512) 59 (668) 19 (686) 45 (667) 72 (686)
Brownstein et al. 2009 
[35]
Ros NR 133 (1879) NR NR NR
Met NR 1174 (23690) NR NR NR
Breunig et al. 2014 [36] Ros; 59 (310) NR NR NR NR
Pla 389 (5548) NR NR NR NR
Dargie et al. 2007 [37] Ros; 19 (110) 5 (110) 2 (110) 5 (110) 8 (110)
Pla 10 (114) 1 (114) 2 (114) 4 (114) 5 (114)
Florez et al. 2015 [38] Ros NR 4 (93) 2 (93) 5 (93) NR
con NR 11 (93) 6 (93) 10 (93) NR
Gerstein et al. 2006 [39] Ros 14 (2635) 16 (2635) 7 (2635) 12 (2635) 30 (2635)
Pla 2 (2634) 9 (2634) 3 (2634) 10 (2634) 33 (2634)
Gram et al. 2011 [40] Ros ± Asp Ins ± 
Met ± NPH In
5 (187) NR 2 (187) 0 (187) 2 (187)
Plac ± Asp Ins ± 
Met ± NPH In
3 (184) NR 3 (184) 0 (184) 2 (184)
Hällsten et al. 2002 [41] Ros NR 0 (14) NR 0 (14) 0 (14)
Met NR 1 (13) NR 0 (13) 0 (13)
Home et al. 2007 [42] Ros 47 (2220) 49 (2220) 109 (2220) 37 (2220) 74 (2220)
Met or gly 22 (2227) 40 (2227) 114 (2227) 46 (2227) 80 (2227)
Kahn et al. 2006 [6] Ros 22 (1456) 25 (1456) 16 (1456) 5 (1456) 34 (1456)
Met or gly 28 (2895) 36 (2895) 36 (2895) 12 (2895) 62 (2895)
Loebstein et al. 2010 
[43]
Ros 56 (745) 13 (745) NR 30 (745) 40 (745)
Met 442 (11938) 131 (11938) NR 418 (11938) 734 (11938)
Mcafee et al. 2007 [44] Ros 205 (8977) 70 (8977) NR NR NR
Met or Sul 136 (8977) 62 (8977) NR NR NR
Mcgavocket al. 2011 
[45]
Ros 2 (26) 5 (26) NR 0 (26) 0 (26)
Met or gly 1 (23) 2 (23) NR 0 (23) 0 (23)
Mcguire et al. 2010 [46] Ros 3 (54) NR NR 0 (54) 0 (54)
Pla 0 (54) NR NR 0 (54) 0 (54)
Varghese et al. 2009 
[47]
Ros 2 (27) 2 (27) NR 0 (27) 0 (27)
Pla 0 (29) 1 (29) NR 0 (29) 0 (29)
Abbreviation: Ros, Rosiglitazone; Met, Metformin; Plac, Placebo; Ros, Rosiglitazone; Sul, Sulfonylurea; Con, Control
for heart failure. We undertook a sensitivity analysis 
replacing data from the longer-term follow-up of the 
two studies [33, 41] with the original published data [6]. 
This led to small changes in the pooled estimates that 
more strongly favoured rosiglitazone for risk of heart 
failure and the risk of myocardial infarction. The funnel 
map (Fig. 8) does not show that rosiglitazone has a risk 
of increasing mortality.
Sensitivity analysis
We performed sensitivity analyses using pooling meth-
ods and statistical models regarding heterogeneity, and 
the cardiovascular events (heart failure, MI, and stroke) 
were similar.
There was little or no heterogeneity in the meta-
analysis of cardiovascular events, suggesting a consist-
ent treatment effect. After excluding the trial with the 
389












Figure 3. Forest plot showing the effect of rosiglitazone on risk of heart failure
Rycina 3. Wykres typu forest plot, przedstawiający wpływ rozyglitazonu na ryzyko wystąpienia niewydolności serca
Figure 4. Forest plot showing the effect of rosiglitazone on risk of myocardial infarction
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smallest number of participants, observational studies, 
and shortest follow-up, the analysis of heart failure (RR 
2.14; 95% CI 1.49–3.05; P < 0.001), MI (RR 1.35; 95% 
CI 1.00–1.83; P = 0.05), and stroke (RR 0.96; 95% CI 
0.76–1.22; P = 0.74) with rosiglitazone from the three 
large trials of similar duration was similar.
Discussion
The meta-analysis included 11 randomised controlled 
trials and observational studies with over 20,000 par-
ticipants with T2DM allocated to rosiglitazone. Though 
it was uncertainty about whether it reduces risk of 
Figure 5. Forest plot showing the effect of rosiglitazone on risk of stroke
Rycina 5. Wykres typu forest plot, przedstawiający wpływ rozyglitazonu na ryzyko wystąpienia udaru
Figure 6. Forest plot showing the effect of rosiglitazone on risk of cardiovascular death
Rycina 6. Wykres typu forest plot, przedstawiający wpływ rozyglitazonu na ryzyko śmierci z powodu choroby sercowo-naczyniowej
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cardiovascular disease. In this review compared with 
a control group, we have summarised the adverse 
effects of the rosiglitazone group as an approximate 
doubling of the risk of heart failure, with an increase in 
the risk of the other cardiovascular events (e.g. MI and 
stroke), cardiovascular mortality, and all-cause mortality 
without any difference. In the results there are only five 
randomised, controlled cardiovascular endpoint trials 
simply comparing rosiglitazone with placebo among 
patients with type T2DM. We found that rosiglitazone 
significantly increases the risk of heart failure and MI 
compared with other basal-bolus insulin regimens. 
These data show rosiglitazone and basal insulin com-
bination treatment as a therapeutic strategy that can 
improve the management of T2DM. We analysed some 
cardiovascular events and used sensitivity analysis to 
adjudicated cardiovascular events that did not change 
the direction or magnitude of the effect.
Two previous meta-analyses showed that the risk of 
MI was significantly increased by rosiglitazone [22, 23]. 
One involving 42 RCTs with 14,237 participants deter-
mined the incidence of MI in the rosiglitazone com-
pared with controls (RR 1.31; 95% CI 1.01–1.70) [22]. The 
other analysis involving 42 RCTs with 28,443 patients 
reported an increase in the risk of MI with rosiglitazone 
compared with controls (RR 1.43; 95% CI 1.03–1.98; 
P = 0.03) [23]. Our analyses included long-term trials 
showing that the RR estimate of 1.41 for MI is similar 
to the OR estimate of 1.43 obtained by two authors. 
A recent analysis reported that TZDs did not increase 
the risk of hypoglycaemia compared with controls; 
a possible mechanism for this is the fact that TZDs are 
mainly metabolized by the liver [17]. Several previous 
studies [24, 25] found, compared with active drugs, that 
metformin, rosiglitazone, and sulfonylurea had similar 
hypoglycaemic effect, which explained that the changes 
of HbA1c and FPG had no statistical significance. Our 
Figure 7. Forest plot showing the effect of rosiglitazone on risk of all-cause mortality
Rycina 7. Wykres typu forest plot, przedstawiający wpływ rozyglitazonu na ryzyko śmierci niezależnie od przyczyny
Figure 8. Funnel plot of effect size estimates for all-cause mortality
Rycina 8. Wykres lejkowy oszacowania wielkości efektu dla 
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findings were consistent with published meta-analyses 
that found that rosiglitazone can increase the risk of MI, 
stroke, or heart failure [8, 26].
All trials of the analyses suggested the possibility of 
bias or lack of information to evaluate the risk of bias. Most 
data for this review came from previous data [6, 39, 42, 43] 
that lacked recent experimental data. One study [35] 
shown patients with the bypass angioplasty revasculari-
sation investigation T2DM, that had some limited for 
analysis. The data from the four observational studies 
[35, 36, 43, 44] were rather heterogeneous. Those were 
seminal trials concerning the effectiveness and safety 
of treatments for T2DM, albeit exhibiting a number of 
previously discussed limitations that might influence 
interpretation [27]. The analyses lack of placebo and 
double-blinding, ‘subgroup’ nature, lack of statistical 
significance of the update threshold, possible differ-
ences in the management of other cardiovascular risk 
factors between groups, and control of blood glucose 
levels in the control group the current standard is 
poor. In short, the research limitations included: 
1. limited data on random trials, and inaccurate risk ratio. 
2. Wide confidence intervals due to the small numbers. 
3. Whether MI and heart failure have information on the 
time was unavailable, which affects the calculation of 
hazard ratios. 4. Whether patients with cardiovascular 
disease and severity before experimental study, which 
have consequences for the outcome.
Rosiglitazone can reduce the blood sugar in people 
with T2DM by increasing the sensitivity of the tissue 
to insulin. Rosiglitazone may increase the incidence of 
oedema, which raises concerns about the use of these 
drugs in heart failure patients [28]. In addition to the 
hypoglycaemic effect, rosiglitazone is beneficial to the 
cardiovascular system by activating the body fluid, 
thrombus, and PPAR receptors on the endothelium [29]. 
Studies have suggested that rosiglitazone and pioglita-
zone are used in patients with heart failure or worsen, 
especially those that are in combination with insulin 
[30]. In the management of T2DM, the attainment of 
glycaemic targets is compromised by the limitation of 
available treatment. With some anti-diabetic treatments 
(e.g. sulfonylureas, insulin), there is an increased risk of 
hypoglycaemia as glucose concentrations approach the 
desired normal range. Other drugs (e.g. rosiglitazone, 
insulin) are associated with weight gain, an undesirable 
effect in patients with T2DM [31]. 
The use of cardio-protective drugs to control cardio-
vascular risk factors during the study may help reduce 
the risk of rosiglitazone damage. The cardiovascular 
differences between rosiglitazone and pioglitazone 
may be partly explained by different effects of lipids 
and lipoproteins, granules, and subclasses [32, 33]. If 
the excessive adverse effects of MI are mediated by 
LDL cholesterol and triglyceride rosiglitazone, it is pos-
sible to have sufficient fat to control statins, which can 
reduce the risk of MI. Aspirin also can reduce the risk 
of diabetes and coronary heart disease. The use, among 
patients with hypertension and diabetes, of angiotensin 
converting enzyme inhibitors or angiotensin receptor 
blockers may have an impact on cardiovascular adverse 
ketone, which can recede the protection of the heart. 
So the analysis should be based on the hierarchical use 
of these drugs as additional clinical data at lower risk 
of heart failure using Rogge column.
Although further research is needed to determine 
the best treatment method in practical application, 
our results clearly illustrate the effect of rosiglitazone 
on the cardiovascular system in the clinical treatment 
of patients with T2DM. The analyses have potential 
Table III. Risk of cardiovascular events and mortality in patients with T2DMs
Tabela III. Ryzyko zdarzeń sercowo-naczyniowych i śmiertelności u pacjentów z cukrzycą typu 2
Outcomes No. of Study Events/Total RR (95% CI) P Value I2
Rosiglitazone Control
Heart failure 9 RCTs 175/7227 116/8672 1.71 [1.36, 2.15] < 0.0001 15%
3 observational studies 320/10032 967/26463 1.84 [1.60, 2.13] < 0.0001 85%
MI 9 RCTs 157/7249 159/8696 1.12 [0.90,1.39] 0.30 34%
3 observational studies 216/11601 1367/44605 1.36 [1.17, 1.58] < 0.0001 0%
Stroke 7 RCTs 152/7387 185/8833 0.91 [0.74, 1.13] 0.39 0%
Cardiovascular Mortality 11 RCT 112/7489 127/8933 0.93 [0.72, 1.19] 0.55 0%
1 observational studies 142/8234 545/20870 1.15 [0.80, 1.65] 0.45 0%
All-cause Mortality 10 RCTs 222/7415 254/8859 1.00 [0.84, 1.19] 0.99 0%
1 observational studies 40/745 734/11938 0.87 [0.64,1.19] 0.39 0% 
Abbreviation: RCTs, Randomised, controlled trials; RR Relative risk; MI, myocardial infarction
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regulatory and clinical implications. These data suggest 
that rosiglitazone reverses the hazard equilibrium. At 
present, clinical treatment of diabetes has a more secure 
program. Regulators should reassess the clinical value 
of rosiglitazone. Diabetes patients should avoid the risk 
of cardiovascular events associated with rosiglitazone 
in safer treatment.
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